| # | Drug | Count |
|---|---|---|
| 0 | IRBESARTAN | 6 |
| 1 | DENOSUMAB | 5 |
| 2 | INFLIXIMAB | 5 |
| 3 | PREDNISONE | 5 |
| 4 | GOLIMUMAB | 4 |
| 5 | HYDROXYCHLOROQUINE SULFATE | 4 |
| 6 | MIRTAZAPINE | 4 |
| 7 | SECUKINUMAB | 4 |
| 8 | VENLAFAXINE HYDROCHLORIDE | 4 |
| 9 | DICLOFENAC SODIUM | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | L-LYSINE | 1 | 0.0014 |
| 1 | ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC-VWF-XTEN FUSION PROTEIN-EHTL | 1 | 0.0006 |
| 2 | FOSPHENYTOIN SODIUM | 1 | 0.0004 |
| 3 | CAPIVASERTIB | 1 | 0.0003 |
| 4 | GOLIMUMAB | 4 | 0.0003 |
| 5 | DICLOFENAC SODIUM AND MISOPROSTOL | 2 | 0.0003 |
| 6 | INFLIXIMAB-DYYB | 1 | 0.0003 |
| 7 | ZIPRASIDONE | 1 | 0.0003 |
| 8 | AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | 1 | 0.0002 |
| 9 | GLYCOPYRROLATE | 1 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Tumor Necrosis Factor Blocker [EPC] | 10 |
| 1 | Corticosteroid [EPC] | 9 |
| 2 | Angiotensin 2 Receptor Blocker [EPC] | 7 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 6 |
| 4 | Interleukin-17A Antagonist [EPC] | 5 |
| 5 | RANK Ligand Inhibitor [EPC] | 5 |
| 6 | Atypical Antipsychotic [EPC] | 4 |
| 7 | Kinase Inhibitor [EPC] | 4 |
| 8 | Vitamin B12 [EPC] | 4 |
| 9 | Vitamin C [EPC] | 4 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-17A Antagonist [EPC] | 5 | 0.0001 |
| 1 | Prostaglandin E1 Analog [EPC] | 2 | 0.0001 |
| 2 | Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] | 1 | 0.0000 |
| 3 | Androgen Receptor Inhibitor [EPC] | 2 | 0.0000 |
| 4 | Estrogen Receptor Antagonist [EPC] | 1 | 0.0000 |
| 5 | RANK Ligand Inhibitor [EPC] | 5 | 0.0000 |
| 6 | Protease Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Angiotensin 2 Receptor Blocker [EPC] | 7 | 0.0000 |
| 8 | Hepatitis C Virus NS5A Inhibitor [EPC] | 1 | 0.0000 |
| 9 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 1 | 0.0000 |